Inhibition of miR-193a expression by max and RXRα activates K-ras and PLAU to mediate distinct aspects of cellular transformation

Cancer Research

Volumn 71, Issue 15, 2011, Pages 5144-5153

  Iliopoulos, Dimitrios ^a   Rotem, Asaf ^a   Struhl, Kevin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAX PROTEIN; MICRORNA; MICRORNA 193A; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENICITY; CELL TRANSFORMATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CORRELATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE PLAU; PRIORITY JOURNAL; PROMOTER REGION; RNA ANALYSIS; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BREAST; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENES, SRC; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RANDOM ALLOCATION; RETINOID X RECEPTOR ALPHA; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 79960970390     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0425     Document Type: Article

References (28)

1. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010;17:348-61.
2. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF10. Cancer Res 1990;50:6075-86. (Pubitemid 20331424)
3. Aziz N, Cherwinski H, McMahon M. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. Mol Cell Biol 1999;19:1101-15. (Pubitemid 29046853)
4. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells and acts together with chemotherapy to blocks tumor growth and prolong remission. Cancer Res 2009;69:7507-11.
5. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kB, lin 28, let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
6. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8. (Pubitemid 29361801)
7. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b, via PTEN and CYLD, are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506.
8. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
9. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009;136:586-91.
10. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev 2009;10:704-14.
11. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011;108:1397-402.
12. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010;39:761-72.
13. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592-603.
14. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.
15. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105. (Pubitemid 351521781)
16. Carmuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C, et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010;130:2062-70.
17. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009;28:3937-48.
18. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010;127:1363-72.
19. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. MicroRNA-193b regulates proliferation, migration, and invasion in human hepatocellular carcinoma cells. Eur J Cancer 2010;46:2828-36.
20. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion, and signaling. FEBS Lett 2010;584:1923-30.
21. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308. (Pubitemid 46480970)
22. Warner JB, Philippakis AA, Jaeger SA, He FS, Lin J, Bulyk ML. Systematic identification of mammalian regulatory motifs' target genes and functions. Nat Methods 2008;5:347-53. (Pubitemid 351459368)
23. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
24. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008;112:4202-12.
25. Mu YM, Yanase T, Nishi Y, Hirase N, Goto K, Takayanagi R, et al. A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells. Mol Cell Endocrinol 2000;166:137-45.
26. Pandey KK, Batra SK. RXRalpha: a novel target for prostate cancer. Cancer Biol Ther 2003;2:185-6.
27. Peng X, Yun D, Christov K. Breast cancer progression in MCF10A series of cell lines is associated with alterations in retinoic acid and retinoid X receptors and with differential response to retinoids. Int J Oncol 2004;25:961-71.
28. Zeisig BB, Kwok C, Zelent A, Shankaranarayanan P, Gronemeyer H, Dong S, et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007;12:36-51. (Pubitemid 47018239)